Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension: Final Results of the Systolic Hypertension in the Elderly Program (SHEP)
Source: View publication →
The SHEP trial demonstrated that low-dose antihypertensive therapy in older patients with isolated systolic hypertension significantly reduces the risk of stroke and major cardiovascular events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SHEP trial provided the landmark evidence required to establish the clinical mandate for treating isolated systolic hypertension in elderly patients, fundamentally altering hypertension management guidelines by demonstrating that lowering systolic pressure—not just diastolic—significantly prevents stroke and major cardiovascular morbidity in older populations.
Historical Context
Prior to SHEP, there was significant medical debate and 'misguided concern' regarding the safety of lowering elevated systolic blood pressure in the elderly, with fears that it might induce hypoperfusion of vital organs. The SHEP trial, along with the later STOP-Hypertension study, definitively dispelled these concerns and established the efficacy and safety of low-dose, step-wise antihypertensive therapy in this high-risk population.
Guided Discussion
High-yield insights from every perspective
What is the primary pathophysiological mechanism behind isolated systolic hypertension in the elderly, and how does chlorthalidone's mechanism of action directly counteract the cardiovascular risks associated with this condition?
Key Response
In older adults, isolated systolic hypertension (ISH) is primarily driven by arterial stiffening and loss of compliance in the large elastic arteries, leading to increased pulse wave velocity and increased systolic pressure. Chlorthalidone, a thiazide-like diuretic, reduces stroke risk by decreasing extracellular fluid volume and, more importantly in the long term, reducing peripheral vascular resistance. This lowers the pressure load on the stiffened vasculature, preventing end-organ damage like cerebral hemorrhage or lacunar infarcts.
In an elderly patient with isolated systolic hypertension (SBP 170 mmHg, DBP 80 mmHg), how does the SHEP trial justify the use of low-dose diuretics over other classes, and what metabolic side effects must be prioritized during the first 3-6 months of therapy?
Key Response
SHEP demonstrated a 36% reduction in stroke risk using low-dose chlorthalidone (12.5-25mg). Unlike high-dose diuretic therapy, low-dose therapy balances efficacy with a lower risk of adverse metabolic profiles. However, clinicians must vigilantly monitor for hyponatremia, hypokalemia, and hyperuricemia, as the elderly are more susceptible to electrolyte shifts that can lead to falls, confusion, or cardiac arrhythmias during the initial treatment phase.
The SHEP trial reported a significant reduction in stroke, but how should we interpret the 'J-curve' phenomenon regarding diastolic blood pressure when treating isolated systolic hypertension to a target SBP <140 mmHg in patients with comorbid coronary artery disease?
Key Response
A critical nuance in treating ISH is the potential to drive diastolic blood pressure (DBP) too low (<60-65 mmHg). Since coronary perfusion occurs primarily during diastole, aggressive reduction of SBP in patients with baseline low DBP may paradoxically increase the risk of myocardial infarction. Fellows must integrate the SHEP findings with the understanding that while stroke risk is highly SBP-dependent, myocardial safety requires careful monitoring of the DBP floor.
Given the 'Number Needed to Treat' (NNT) of 31 to prevent one stroke over five years in the SHEP trial, how do you integrate these findings into shared decision-making for an 85-year-old patient with multiple comorbidities and high fall risk?
Key Response
The attending must move beyond the statistically significant results to clinical utility. An NNT of 31 is robust for primary prevention, but the clinician must weigh the 'stroke-free survival' against the 'burden of therapy.' In the very elderly, the trade-off includes the risk of orthostatic hypotension and subsequent fractures versus the high morbidity of a disabling stroke, requiring a personalized approach rather than a rigid adherence to the trial's mean age and health status.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SHEP trial employed a 'stepped-care' protocol (chlorthalidone followed by atenolol). How does this design impact the internal validity of attributing outcomes solely to thiazide-like diuretics, and what modern causal inference framework could better isolate the effect of the primary agent?
Key Response
Stepped-care designs introduce 'treatment contamination' where the secondary drug (atenolol) might contribute to the observed benefit, confounding the effect of the primary drug. From a research methodology perspective, using a Marginal Structural Model (MSM) with inverse probability weighting could help account for time-varying confounding, where the decision to add atenolol is influenced by the blood pressure response to the initial chlorthalidone dose.
The SHEP trial had a high rate of 'crossover'—where placebo patients were started on active antihypertensive therapy by their primary physicians. How should this 'contamination' influence our appraisal of the reported Hazard Ratios, and was an Intention-to-Treat (ITT) analysis sufficient to mitigate this?
Key Response
Contamination (placebo group receiving active treatment) typically biases results toward the null, meaning the true effect size of the intervention might be even larger than what was reported in SHEP. While ITT is the standard to preserve randomization, a seasoned reviewer would request a 'per-protocol' or 'as-treated' sensitivity analysis to understand the maximum potential benefit, while acknowledging that ITT provides the most conservative and pragmatic estimate for real-world application.
SHEP used a threshold of 160 mmHg for treatment, whereas current ACC/AHA guidelines suggest a threshold of 130 mmHg. Does the SHEP evidence support these lower targets for the elderly, or does it primarily validate the efficacy of the drug class rather than the specific BP target?
Key Response
SHEP remains the foundational evidence for the Grade A/Class 1 recommendation for thiazide-like diuretics in ISH. However, SHEP only validated the benefit for SBP >160 mmHg. Modern guidelines (like the 2017 ACC/AHA) extrapolated from later trials like SPRINT to lower the threshold to 130 mmHg. The committee must distinguish between 'class efficacy' (proven by SHEP) and 'target intensity' (which requires integration of more recent, aggressive trial data while noting the higher adverse event rates in those cohorts).
Clinical Landscape
Noteworthy Related Trials
Syst-Eur Trial
Tested
Nitrendipine-based antihypertensive regimen
Population
Elderly patients aged 60+ with isolated systolic hypertension
Comparator
Placebo
Endpoint
Fatal and non-fatal stroke
HYVET Trial
Tested
Indapamide +/- perindopril
Population
Patients aged 80+ with hypertension
Comparator
Placebo
Endpoint
Fatal or non-fatal stroke
SPRINT Trial
Tested
Intensive systolic blood pressure target (<120 mmHg)
Population
Hypertensive adults aged 50+ at high cardiovascular risk
Comparator
Standard systolic blood pressure target (<140 mmHg)
Endpoint
Composite of myocardial infarction, acute coronary syndromes, stroke, HF, or death from CV causes
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis